Theravance (THRX +2.4%) and GlaxoSmithKline (GSK +0.6%) have submitted a New Drug Application for the investigational drug UMEC/VI (LAMA/LABA), named Anoro Ellipta, which is a potential treatment for patients with chronic obstructive pulmonary disease. The companies also intend to file regulatory applications in the European Union as well as other countries in the coming year.
Theravance (THRX +2.4%) and GlaxoSmithKline (GSK +0.6%) have submitted a New Drug Application...
From other sites
at CNBC.com (Jun 11, 2014)
at CNBC.com (Dec 6, 2013)
at CNBC.com (Sep 10, 2013)
at CNBC.com (Jun 24, 2013)
at CNBC.com (Apr 15, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs